Bristol-Myers Squibb Stock Outlook: Is Wall Street Bullish or Bearish?

Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) is a leading biopharmaceutical company focused on developing treatments for serious diseases such as cancer, inflammatory, immunologic, cardiovascular, and fibrotic diseases. With a market cap of $111.2 billion, its strong oncology portfolio includes blockbuster drug Opdivo and other drugs like Revlimid, Pomalyst, Sprycel, Yervoy, and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. 

Shares of this biopharma giant have considerably underperformed the broader market over the past year. BMY has declined 8.3% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 16.1%. Over the past six months, however, the stock has climbed 14.7%, surpassing the SPX’s 9.2%.